Skip to main content

Featured

Futures Steady as Tech Selloff Eases; Amazon Drops on AI Spending Surge

U.S. stock futures held steady in early premarket trading after a sharp tech-led decline earlier in the week, giving investors a moment to reassess the sector’s rapid pullback. Major index futures hovered near flat, suggesting a more measured tone after days of volatility. While sentiment remains cautious, some traders appear to be stepping back in following the recent selloff in high‑growth names. Amazon shares slipped in premarket action after the company signaled a significant increase in capital expenditures tied to artificial intelligence infrastructure. The planned investment highlights Amazon’s push to expand its AI capabilities, but the scale of spending raised concerns about near‑term pressure on margins. Market attention now turns to upcoming economic data and corporate earnings, which could help determine whether tech stocks regain momentum or continue to face headwinds. For the moment, futures point to a steadier start as investors look for the next catalyst.
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment